natgillin/translations-raw huggingface dataset:
The main metabolite in plasma, the glucuronide conjugate of silodosin (KMD-3213G), that has been shown to be active in vitro, has an extended half-life (approximately 24 hours) and reaches plasma concentrations approximately four times higher than those of silodosin. 
Glavni metabolit u plazmi, konjugat silodozina s glukuronidom (KMD-3213G), koji se pokazao djelatan in vitro, ima produljeni poluvijek (približno 24 sata) i postiže koncentracije u plazmi približno četiri puta veće od onih koje postiže silodozin.
Intraoperative Floppy Iris Syndrome (IFIS) 
Intraoperacijski sindrom meke šarenice (IFIS)
In an interaction study, a 3.7-fold increase in maximum silodosin plasma concentrations and a 3.1-fold increase in silodosin exposure (i.e. AUC) were observed with concurrent administration of a potent CYP3A4 inhibitor (ketoconazole 400 mg). 
U ispitivanju interakcija primijećeno je 3,7-struko povećanje maksimalnih koncentracija silodozina u plazmi i 3,1-struko povećanje izloženosti silodozinu (tj. AUC) kad se istovremeno primjenjivao jaki inhibitor CYP3A4 (ketokonazol 400 mg).
If you have severe kidney problems, you should not take Silodosin Recordati. 
Ako imate teške tegobe s bubrezima, ne biste smjeli uzimati Silodozin Recordati.
• Runny or blocked nose 
• curenje iz nosa ili začepljen nos
If dizziness when standing up or fainting occurs, please inform your doctor as soon as possible. 
Ako nastane omaglica ili nesvjestica kod ustajanja, molimo čim prije obavijestite liječnika.
This effect disappears after discontinuation of silodosin (see section 4.8). 
Ovaj učinak nestaje nakon prestanka uzimanja silodozina (vidjeti dio 4.8).
What Silodosin Recordati is and what it is used for What you need to know before you take Silodosin Recordati How to take Silodosin Recordati Possible side effects 
Što je Silodozin Recordati i za što se koristi Što morate znati prije nego počnete uzimati Silodozin Recordati Kako uzimati Silodozin Recordati
Silodosin is highly selective for α1A-adrenoreceptors that are primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. 
Silodozin je visoko selektivan prema α1A-adrenergičkim receptorima koji se primarno nalaze u ljudskoj prostati, dnu mokraćnog mjehura, vratu mokraćnog mjehura, kapsuli prostate i prostatičnom dijelu uretre.
For special patient populations, one capsule of Silodosin Recordati 4 mg daily is recommended (see below). 
Kod posebnih populacija bolesnika, preporučuje se jedna kapsula lijeka Silodozin Recordati 4 mg na dan (vidjeti niže).
Other medicines and Silodosin Recordati 
Drugi lijekovi i Silodozin Recordati
The most frequent adverse reactions reported with silodosin in placebo controlled clinical studies and during long-term use were ejaculatory disorders such as retrograde ejaculation and anejaculation (ejaculatory volume reduced or absent), with a frequency of 23%. 
Najčešće nuspojave zabilježene uz silodozin u placebom kontroliranim kliničkim ispitivanjima i za vrijeme dugotrajnog uzimanja bile su poremećaji ejakulacije, kao što je retrogradna ejakulacija i izostanak ejakulacije (smanjen volumen ejakulata ili izostanak ejakulata) s učestalosti od 23%.
• medicines for epilepsy or rifampicin (a medicine to treat tubercolosis), since the effect of Silodosin Recordati may be reduced. 
• lijekove protiv epilepsije ili rifampicin (lijek za liječenje tuberkuloze), budući da mogu smanjiti učinak lijeka Silodozin Recordati.
In all studies, patients who did not respond to placebo during a 4-week placebo run-in phase were randomised to receive the study treatment. 
U svim ispitivanjima, bolesnici koji nisu imali odgovor na placebo tijekom uvodne placebo faze u trajanju od
• antifungal medicines (such as ketoconazole or itraconazole), medicines used for HIV-AIDS (such as ritonavir) or medicines used after transplants to prevent organ rejection (such as cyclosporin) because these medicines can increase the blood concentration of Silodosin Recordati. 
• lijekove protiv gljivica (kao što su ketokonazol ili itrakonazol), lijekove koji se primjenjuju kod HIV-a/SIDA-e (kao što je ritonavir) ili lijekove koji se koriste nakon presađivanja organa da bi se spriječilo njegovo odbacivanje (kao što je ciklosporin), zato što ti lijekovi mogu povećati koncentraciju lijeka Silodozin Recordati u krvi.
In healthy male subjects of the target age range (n = 16, mean age 55 ± 8 years) after once-a-day oral administration of 8 mg immediately after breakfast for 7 days, the following pharmacokinetic parameters were obtained: Cmax 87 ± 51 ng/mL (sd), tmax 2.5 hours (range 1.0-3.0), AUC 433 ± 286 ng • h/mL. 
U zdravih muških ispitanika u ciljnom dobnom rasponu (n = 16, srednja vrijednost dobi 55 ± 8 godina) nakon peroralne primjene 8 mg jedanput na dan neposredno nakon doručka tijekom 7 dana, dobili su se sljedeći farmakokinetički parametri: Cmax 87 ± 51 ng/ml (sd), tmax 2,5 sati
• If you are undergoing eye surgery because of cloudiness of the lens (cataract surgery), it is important that you immediately inform your eye specialist that you are using or have previously used Silodosin Recordati. 
• Ako idete na operaciju oka zbog zamućenja leće (operacija katarakte), važno je da odmah obavijestite svog specijalistu za liječenje očnih bolesti da uzimate ili da ste prije uzimali
Silodosin undergoes extensive metabolism through glucuronidation (UGT2B7), alcohol and aldehyde dehydrogenase and oxidative pathways, mainly CYP3A4. 
Biotransformacija Silodozin se opsežno metabolizira glukuronidacijom (UGT2B7), alkoholnom i aldehidnom dehidrogenazom i oksidativnim metaboličkim putevima, uglavnom putem CYP3A4.
Do not take Silodosin Recordati if you are allergic to silodosin or any of the other ingredients of this medicine (listed in section 6). 
Što morate znati prije nego počnete uzimati Silodozin Recordati Nemojte uzimati Silodozin Recordati ako ste alergični na silodozin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
• The treatment with Silodosin Recordati may lead to an abnormal ejaculation (decrease in the amount of semen released during sex) that may temporarily affect male fertility. 
• Liječenje lijekom Silodozin Recordati može dovesti do poremećaja ejakulacije (smanjenja količine sjemena koje se oslobađa u spolnom odnosu), što može privremeno narušiti plodnost u muškarca.
Plasma level monitoring in a Phase III clinical study showed that levels of total silodosin after 4 weeks of treatment did not change in patients with mild impairment (n = 70), compared to patients with normal renal function (n = 155), while the levels were doubled on average in patients with moderate impairment (n = 7). 
Praćenje razine u plazmi u Fazi III kliničkog ispitivanja pokazalo je da se razine ukupnog silodozina nakon 4 tjedna liječenja nisu promijenile u bolesnika s blagim oštećenjem funkcije bubrega (n = 70) u usporedbi s bolesnicima s normalnom funkcijom bubrega (n = 155), dok su razine u prosjeku bile udvostručene u bolesnika s umjerenim oštećenjem funkcije bubrega (n = 7).
This effect disappears after discontinuation of Silodosin Recordati. 
Ovaj učinak nestaje nakon prestanka uzimanja lijeka Silodozin Recordati.
Silodosin is excreted mainly as metabolites, very low amounts of unchanged drug are recovered in urine. 
Silodozin se uglavnom izlučuje u obliku metabolita, dok se neizmijenjeni lijek može pronaći u mokraći u vrlo malim količinama.
Do not drive or operate machines if you feel faint, dizzy, drowsy or have blurred vision. 
Nemojte upravljati vozilima niti raditi sa strojevima ako Vam prijeti nesvjestica, osjećate omaglicu,
In clinical studies, the occurrence of ejaculation with reduced or no semen has been observed during treatment with silodosin (see section 4.8), due to the pharmacodynamic properties of silodosin. 
U kliničkim je ispitivanjima za vrijeme liječenja silodozinom primijećena pojava ejakulacije sa smanjenom količinom sjemena ili bez sjemena (vidjeti dio 4.8) zbog farmakodinamičkih svojstava silodozina.
By blocking these receptors, it causes smooth muscle in these tissues to relax. 
Blokiranjem ovih receptora, Silodozin Recordati uzrokuje opuštanje glatkih mišića u tim tkivima.
The most common side effect is a decrease in the amount of semen released during sex. 
Najčešća nuspojava je smanjena količina sperme koje se oslobađa kod spolnog odnosa.
What Silodosin Recordati looks like and contents of the pack 
Kako Silodozin Recordati izgleda i sadržaj pakiranja
Silodosin Recordati has minor or moderate influence on the ability to drive and use machines. 
Silodozin Recordati malo do umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Treatment with silodosin leads to a decrease in the amount of semen released during orgasm that may temporarily affect male fertility. 
Liječenje silodozinom dovodi do smanjenja količine sperme koja se oslobađa tijekom orgazma, što može privremeno smanjiti plodnost kod muškarca.
The terminal half-life of parent drug and its glucuronide is approximately 11 hours and 18 hours, respectively. 
Terminalni poluvijek prekursora iznosi približno 11 sati,
Patients with kidney problems 
Bolesnici koji imaju tegobe s bubrezima
• medicines used for treating problems in getting or keeping an erection (such as sildenafil or tadalafil), since the concomitant use with Silodosin Recordati might lead to a slight decrease in blood pressure. 
• lijekove koji se primjenjuju u liječenju otežanog postizanja i održavanja erekcije (kao što su sildenafil ili tadalafil), budući da istovremeno uzimanje lijeka Silodozin Recordati može dovesti do sniženja krvnog tlaka.
Injury, poisoning and procedural complication 
Ozljede, trovanja i proceduralne komplikacije intraoperacijski sindrom meke šarenice
In the table below, adverse reactions reported in all clinical studies and in the worldwide post-marketing experience for which a reasonable causal relationship exists are listed by MedDRA system organ class and frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from available data). 
manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000), nepoznato
Silodosin and its glucuronide reach steady-state after 3 days and 5 days of treatment, respectively. 
Silodozin postiže stanje dinamičke ravnoteže nakon 3 dana, a njegov glukuronid nakon 5 dana liječenja.
Abnormal liver function tests1 
Poremećaji jetre i žuči abnormalni nalazi pretraga funkcije jetre1
The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate, gelatin, titanium dioxide (E171), yellow iron oxide (E172). 
Drugi sastojci su prethodno geliran kukuruzni škrob, manitol (E421), magnezijev stearat, natrijev laurilsulfat, želatina, titanijev dioksid (E171), žuti željezov oksid (E172).
The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate, gelatin, titanium dioxide (E171). 
Drugi sastojci su prethodno geliran kukuruzni škrob, manitol (E421), magnezijev stearat, natrijev laurilsulfat, želatina, titanijev dioksid (E171).
The safety of silodosin has been evaluated in four Phase II-III double-blind controlled clinical studies (with 931 patients receiving silodosin 8 mg once daily and 733 patients receiving placebo) and in two long-term open-label extension phase studies. 
Faze II-III (u kojima je 931 bolesnik primao silodozin od 8 mg jedanput na dan, a 733 bolesnika je primalo placebo) i u dva dugotrajna nastavka ispitivanja otvorenog tipa.
The use in patients with severe renal impairment (CLCR < 30 mL/min) is not recommended (see sections 4.4 and 5.2). 
Ne preporučuje se primjena u bolesnika s teškim oštećenjem funkcije bubrega (CLcr < 30 ml/min) (vidjeti dijelove 4.4 i 5.2).
This medicine contains less than 1 mmoL sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po kapsuli, tj. zanemarive količine natrija.
The exposure to the main metabolite in plasma, silodosin glucuronide (KMD-3213G), at steady-state is about 3-fold that of the parent substance. 
Izloženost glavnom metabolitu u plazmi, silodozin glukuronidu (KMD-3213G), u stanju je dinamičke ravnoteže oko 3 puta veća od one ishodišnoj tvari.
In a single-dose study, exposure to silodosin (unbound) in subjects with mild (n = 8) and moderate renal impairment (n = 8) resulted, on average, in an increase of Cmax (1.6-fold) and AUC (1.7-fold) relative to subjects with normal renal function (n = 8). 
U ispitivanju jednokratne doze, izloženost silodozinu (nevezanom) u ispitanika s blagim (n = 8) i umjerenim oštećenjem funkcije bubrega (n = 8) u prosjeku je rezultiralo povećanjem Cmax (1,6 puta) i
Steady state levels of digoxin, a substrate of P-glycoprotein, were not significantly affected by co-administration with silodosin 8 mg once daily. 
Razine digoksina, supstrata P-glikoproteina, u stanju dinamičke ravnoteže nisu bile značajno promijenjene istovremenom primjenom silodozina od 8 mg jedanput na dan.
• Faster heart rate 
• brži otkucaji srca
In the clinical study program, many patients were on concomitant antihypertensive therapy (mostly agents acting on the renin-angiotensin system, beta-blockers, calcium antagonists and diuretics) without experiencing an increase in the incidence of orthostatic hypotension. 
(uglavnom lijekove koji djeluju na sustav renin-angiotenzin, beta-blokatore, antagoniste kalcija i diuretike), a da pritom incidencija ortostatske hipotenzije nije bila povećana.
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'. 
Natrij Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po kapsuli, tj. zanemarive količine natrija.
• difficulty in starting to pass water, 
• otežan početak mokrenja,
As no data are available, the use in patients with severe hepatic impairment is not recommended (see sections 4.4 and 5.2). 
Kako nema dostupnih podataka, ne preporučuje se primjena u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
The pharmacokinetics of silodosin in patients with severe hepatic impairment has not been studied. 
Farmakokinetika silodozina u bolesnika s teškim oštećenjem funkcije jetre nije se ispitivala.
Tachycardia1 Palpitations1 
Srčani poremećaji tahikardija1
Silodosin Recordati is selective for the receptors located in the prostate, bladder and urethra. 
Silodozin Recordati se selektivno veže za receptore koji se nalaze u prostati, mokraćnom mjehuru i mokraćnoj cijevi.
No significant reduction in supine blood pressure was observed in all clinical studies conducted with silodosin. 
Niti u jednom od kliničkih ispitivanja provedenih sa silodozinom nije bilo primijećeno značajno sniženje krvnog tlaka u ležećem položaju.
The pharmacokinetics of silodosin and its main metabolites have been evaluated in adult male subjects with and without BPH after single and multiple administrations with doses ranging from 0.1 mg to 48 mg per day. 
Placebo bez BHP nakon jednokratne i višekratnih primjena doza u rasponu od 0,1 mg do 48 mg na dan.
Hypotension1 
palpitacije1
If you stop taking Silodosin Recordati 
Ako prestanete uzimati Silodozin Recordati
Alpha-blockers There is inadequate information about the safe use of silodosin in association with other α-adrenoreceptor antagonists. 
Nema odgovarajućih podataka o sigurnosti primjene silodozina s drugim antagonistima α-adrenergičkih receptora.
Libido decreased 
Psihijatrijski poremećaji smanjeni libido
Silodosin Recordati 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm). 
Silodozin Recordati 4 mg su žute, neprozirne tvrde želatinske kapsule, veličine 3 (približno 15,9 x 5,8 mm).
Silodosin Recordati 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm). 
Silodozin Recordati 8 mg su bijele, neprozirne, tvrde želatinske kapsule, veličine 0 (približno 21,7 x 7,6 mm).
Orthostatic effects 
Ortostatski učinci
Very rare side effects (may affect up to 1 in 10,000 people) • Other allergic reactions with swelling of the face or throat 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) • poremećaj ejakulacije (smanjeno ili neprimjetno oslobađanje sjemena u spolnom odnosu,
No dose adjustment is required for patients with mild to moderate hepatic impairment. 
Nije potrebna prilagodba doze kod bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
Approximately half of the patients reported an improvement in the most bothersome symptoms complained at baseline by the patients (i.e. nocturia, frequency, decreased stream, urgency, terminal dribbling and incomplete emptying), as assessed by the ICS-male questionnaire. 
Otprilike polovica bolesnika prijavila je poboljšanje u većini neugodnih simptoma na koje su se žalili na početku (npr. noćno mokrenje, učestalo mokrenje, smanjen mlaz mokraće, hitnost mokrenja,
For this purpose Silodosin Recordati 4 mg hard capsules are available. 
U tu su svrhu dostupne tvrde kapsule Silodozin Recordati od 4 mg.
Study Treatment arm 
Ispitivanje Terapijska skupina
Common Uncommon Rare 
Manje često Rijetko
Since no data are available in patients with severe hepatic impairment, the use of silodosin in these patients is not recommended (see sections 4.2 and 5.2). 
Oštećenje funkcije jetre Budući da nema dostupnih podataka u bolesnika s teškim oštećenjem funkcije jetre, ne preporučuje se primjena silodozina u ovih bolesnika (vidjeti dijelove 4.2 i 5.2).
If you forget to take Silodosin Recordati 
Ako ste zaboravili uzeti Silodozin Recordati
Allergictype reactions including facial swelling, swollen tongue and pharyngeal oedema1 
Poremećaji imunološkog sustava alergijske reakcije uključujući i oticanje lica, oticanje jezika i edem ždrijela1
The recommended dose is one capsule of Silodosin Recordati 8 mg daily. 
Preporučena doza je jedna kapsula lijeka Silodozin Recordati 8 mg na dan.
Total score 
IPSS ukupni rezultat
Following oral administration of 14C-labelled silodosin, the recovery of radioactivity after 7 days was approximately 33.5% in urine and 54.9% in faeces. 
33,5% radioaktivnosti, a u stolici približno 54,9%.
The recommended dose is one capsule of Silodosin Recordati 8 mg per day by oral administration. 
Preporučena doza je jedna kapsula lijeka Silodozin Recordati od 8 mg na dan primjenom kroz usta.
Reproductive system and breast disorders 
Poremećaji reproduktivnog sustava i dojki poremećaji ejakulacije,
In the active-controlled clinical study conducted in Europe, silodosin 8 mg once daily was shown to be non inferior to tamsulosin 0.4 mg once daily: the adjusted mean difference (95% CI) in the IPSS Total Score between treatments in the per-protocol population was 0.4 (-0.4 to 1.1). 
8 mg jedanput na dan nije inferioran tamsulozinu od 0,4 mg jedanput na dan: prilagođena prosječna razlika (95% CI) u ukupnom IPSS rezultatu između terapijskih skupina koje su završile ispitivanje prema planu (engl.
If you have moderate kidney problems, your doctor will start Silodosin Recordati with caution and possibly with a lower dose (see section 3 “Dose”). 
Recordati s oprezom i možda u manjoj dozi (pogledajte dio 3 „Doza“).
Pregnancy and breast-feeding Not applicable as silodosin is intended for male patients only. 
Nije primjenjivo jer je silodozin namijenjen samo za primjenu u muškaraca.
In a Phase II dose-finding, double-blind, placebo-controlled clinical study with silodosin 4 or 8 mg once daily, a greater improvement in American Urologic Association (AUA) symptom index score was observed with silodosin 8 mg (-6.8 ± 5.8, n = 90; p = 0.0018) and silodosin 4 mg (-5.7 ± 5.5, n = 88; p = 0.0355) as compared to placebo (-4.0 ± 5.5, n = 83). 
n = 90; p = 0,0018) i silodozina u dozi od 4 mg (-5,7 ± 5,5, n = 88; p = 0,0355) u odnosu na placebo (-4,0 ± 5,5, n = 83).
How to take Silodosin Recordati 
Kako uzimati Silodozin Recordati
Each capsule contains 4 mg of silodosin. 
Jedna kapsula sadrži 4 mg silodozina.
What Silodosin Recordati is and what it is used for 
Što je Silodozin Recordati i za što se koristi Što je Silodozin Recordati
Irritative symptoms 
IPSS simptomi iritacije
In patients with severe renal impairment administration of Silodosin Recordati is not recommended. 
U bolesnika s teškim oštećenjem funkcije bubrega ne preporučuje se primjena lijeka Silodozin
Each capsule contains 8 mg of silodosin. 
Jedna kapsula sadrži 8 mg silodozina.
No dose adjustment is required for patients with mild renal impairment (CLCR ≥ 50 to ≤ 80 mL/min). 
Nije potrebna prilagodba doze u bolesnika s blagim oštećenjem funkcije bubrega (CLcr ≥ 50 do
Via M. Civitali 1 
Recordati Industria Chimica e Farmaceutica S.p.A. Via M. Civitali 1
Accordingly, no dose adjustment is required in patients with mild renal impairment. 
Sukladno tome, nije potrebno prilagođavati dozu u bolesnika s blagim oštećenjem funkcije bubrega.
Body clearance of silodosin was approximately 0.28 L/h/kg. 
0,28 l/h/kg.
Silodosin Recordati 8 mg hard capsules 
Silodozin Recordati 8 mg tvrde kapsule
In a placebo-controlled study in 24 subjects 45-78 years of age receiving silodosin, the co-administration of sildenafil 100 mg or tadalafil 20 mg induced no clinically meaningful mean decreases in systolic or diastolic blood pressure, as assessed by orthostatic tests (standing versus supine). 
U placebom kontroliranom ispitivanju s 24 ispitanika u dobi od 45 do 78 godina koji su primali silodozin, istovremena primjena sildenafila od 100 mg ili tadalafila od
Respiratory, thoracic and mediastinal disorders 
Poremećaji dišnog sustava, prsišta i sredoprsja kongestija nosa
How to store Silodosin Recordati 
Kako čuvati Silodozin Recordati
In all studies, patients treated with silodosin had a greater decrease in both storage (irritative) and voiding (obstructive) symptoms of BPH as compared to placebo as assessed after 12 weeks of treatment. 
(iritativnih) i mokrenja (opstruktivnih) u usporedbi s placebom na temelju procjene nakon 12 tjedana liječenja.
What Silodosin Recordati is used for 
Za što se Silodozin Recordati koristi
Ejaculatory disorders, including retrograde ejaculation, anejaculation 
uključujući retrogradn u ejakulaciju izostanak ejakulacije erektilna disfunkcija
Patients should be informed about the possible occurrence of symptoms related to postural hypotension (such as dizziness) and should be cautioned about driving or operating machines until they know how silodosin will affect them. 
(kao što je omaglica) i upozoreni da ne voze i ne rade sa strojevima dok ne vide kako na njih utječe silodozin.
INFORMATION IN BRAILLE silodosin recordati 4 mg 
Silodozin Recordati 4 mg
Obstructive symptoms 
IPSS simptomi opstrukcije
Silodosin Recordati 8 mg hard capsules Silodosin Recordati 4 mg hard capsules silodosin 
Silodozin Recordati 4 mg tvrde kapsule Silodozin Recordati 8 mg tvrde kapsule
Lie tuva 
• suha usta
Nervous system disorders 
Poremećaji živčanog sustava omaglica sinkopa, gubitak svijesti1
Ask your doctor whether or not you should postpone or temporarily stop taking Silodosin Recordati when undergoing cataract surgery. 
Upitajte liječnika trebate li odgoditi ili privremeno prekinuti uzimanje lijeka
INFORMATION IN BRAILLE silodosin recordati 8 mg 
silodozin recordati 8 mg
QUALITATIVE AND QUANTITATIVE COMPOSITION Silodosin Recordati 4 mg hard capsules Each hard capsule contains 4 mg silodosin. 
Silodozin Recordati 4 mg tvrde kapsule Jedna tvrda kapsula sadrži 4 mg silodozina.
Very common side effects (may affect more than 1 in 10 people) 
Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 osoba)
NAME OF THE MEDICINAL PRODUCT Silodosin Recordati 4 mg hard capsules silodosin 
Silodozin Recordati 4 mg tvrde kapsule silodozin
Pharmacotherapeutic group: Urologicals, alpha-adrenoreceptor antagonists, ATC code: G04CA04. 
Farmakoterapijska skupina: Lijekovi koji djeluju na mokraćni sustav, alfa-adrenergičkih receptora,
No. of patients 
Br. Bolesnika
NAME OF THE MEDICINAL PRODUCT Silodosin Recordati 8 mg hard capsules silodosin 
Silodozin Recordati 8 mg tvrde kapsule silodozin
Fe rtilty 
Rok valjanosti
There are also links to other websites about rare diseases and treatments. 
Postoje također poveznice na druge web stranice o rijetkim bolestima i liječenjima istih.